Clinical Trial Update: Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

This update reports results from a Phase 1/2 study evaluating the combination of dasatinib and erlotinib in non-small cell lung cancer. Results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DASATINIB (Dasatinib)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer, Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-10-21